{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:02:19Z","timestamp":1789959739418,"version":"4.0.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7\u2013242209-BIOSTAT-CHF"],"award-info":[{"award-number":["FP7\u2013242209-BIOSTAT-CHF"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["EudraCT 2010\u2013020808-29"],"award-info":[{"award-number":["EudraCT 2010\u2013020808-29"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ketone body levels are elevated in patients with heart failure (HF). Recently, plasma levels of ketone bodies have been associated with mortality in patients with HF. However, little is known about the biological processes active in patients with high levels of ketone bodies. The objective of this study was to investigate the features and prognosis of patients with HF with elevated \u03b2-hydroxybutyrate levels. Furthermore, we aimed to determine the specific biological processes that are active in these patients that may result in elevated levels of \u03b2-hydroxybutyrate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\u03b2-hydroxybutyrate concentrations were measured by nuclear magnetic resonance spectroscopy in plasma from 478 patients with HF from the BIOSTAT-CHF cohort. In addition, the concentrations of 1057 circulating proteins were measured by liquid chromatography\u2013mass spectrometry. Differential expression and ingenuity pathway analyses were used to investigate which biological processes are associated with high levels of \u03b2-hydroxybutyrate. Cox regression was used to investigate the association of \u03b2-hydroxybutyrate with mortality and HF hospitalization. Mediation analysis was conducted to determine how much of the association between \u03b2-hydroxybutyrate and outcomes is statistically explained by these processes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort consisted mostly of male patients (64.2%), with equal proportions of HF with reduced ejection fraction and preserved ejection fraction. Elevated \u03b2-hydroxybutyrate levels were independently associated with higher heart rate, lower iron levels, and lower body mass index. Moreover, every doubling of \u03b2-hydroxybutyrate was associated with a 36.4% increase in mortality (unadjusted hazard ratio 1.364: 95% confidence interval 1.089\u20131.707). Even after accounting for known risk factors, the relationship remained highly robust (adjusted hazard ratio 1.389; 95% confidence interval 1.150\u20131.677). Differential expression and ingenuity pathway analyses revealed that higher \u03b2-hydroxybutyrate levels were associated with the upregulation of pathways associated with acute inflammation and cachexia, whereas lipogenic and anabolic pathways were down-regulated. Subsequent multiple mediation analysis showed that 76% of the association between \u03b2-hydroxybutyrate and mortality was explained by these pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated \u03b2-hydroxybutyrate levels predict mortality in chronic HF, independent of established risk factors. Proteomic analysis links elevated \u03b2-hydroxybutyrate to heightened inflammation and catabolism, and these pathways largely mediated the association between \u03b2-hydroxybutyrate and mortality. These findings suggest that elevated ketone bodies may reflect underlying metabolic stress in patients at risk of adverse outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag193","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:26:01Z","timestamp":1789755961000},"source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory and catabolic activity mediate the association of plasma \u03b2-hydroxybutyrate and mortality in heart failure"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6044-1299","authenticated-orcid":false,"given":"Constantin Laurent","family":"Palm","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Groningen and University Medical Center Groningen , Hanzeplein 1, Groningen 9700 RB ,","place":["The Netherlands"]},{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg , Oldenburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9057-7449","authenticated-orcid":false,"given":"Bart J","family":"van Essen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen and University Medical Center Groningen , Hanzeplein 1, Groningen 9700 RB ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Baumhove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen and University Medical Center Groningen , Hanzeplein 1, Groningen 9700 RB ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ridha I S","family":"Alnuwaysir","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen and University Medical Center Groningen , Hanzeplein 1, Groningen 9700 RB ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margery A","family":"Connelly","sequence":"additional","affiliation":[{"name":"Labcorp Diagnostics R&D, , Morrisville, NC 27560 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Petersmann","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg , Oldenburg ,","place":["Germany"]},{"name":"Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald , Greifswald ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Hoegl","sequence":"additional","affiliation":[{"name":"Research and Early Development, Novo Nordisk A\/S , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T","family":"Madsen","sequence":"additional","affiliation":[{"name":"Research and Early Development, Novo Nordisk A\/S , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C","family":"Refgaard","sequence":"additional","affiliation":[{"name":"Development, Novo Nordisk A\/S , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Conde-Knape","sequence":"additional","affiliation":[{"name":"Research and Early Development, Novo Nordisk A\/S , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Barascuk-Michaelsen","sequence":"additional","affiliation":[{"name":"Research and Early Development, Novo Nordisk A\/S , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chim","family":"Lang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Research, University of Dundee , Dundee ,","place":["UK"]},{"name":"Tuanku Muhriz Royal Chair, National University of Malaysia , Kuala Lumpur ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-4415","authenticated-orcid":false,"given":"Adriaan A","family":"Voors","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen and University Medical Center Groningen , Hanzeplein 1, Groningen 9700 RB ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1362-7019","authenticated-orcid":false,"given":"Berend Daan","family":"Westenbrink","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen and University Medical Center Groningen , Hanzeplein 1, Groningen 9700 RB ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092022202928000_xvag193-B1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026092022202928000_xvag193-B2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/heartjnl-2021-320131","article-title":"Prevalence, incidence and survival of heart failure: a systematic review","volume":"108","author":"Emmons-Bell","year":"2022","journal-title":"Heart"},{"key":"2026092022202928000_xvag193-B3","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"key":"2026092022202928000_xvag193-B4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation"},{"key":"2026092022202928000_xvag193-B5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.tem.2023.10.002","article-title":"Mechanisms of hepatic fatty acid oxidation and ketogenesis during fasting","volume":"35","author":"Ruppert","year":"2023","journal-title":"Trends Endocrinol Metab"},{"key":"2026092022202928000_xvag193-B6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/0735-1097(96)00214-8","article-title":"Blood ketone bodies in congestive heart failure","volume":"28","author":"Lommi","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2026092022202928000_xvag193-B7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1126\/science.abc8861","article-title":"Comprehensive quantification of fuel use by the failing and nonfailing human heart","volume":"370","author":"Murashige","year":"2020","journal-title":"Science"},{"key":"2026092022202928000_xvag193-B8","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124079","article-title":"The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense","volume":"4","author":"Horton","year":"2019","journal-title":"JCI Insight"},{"key":"2026092022202928000_xvag193-B9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007684","article-title":"Ketone ester treatment improves cardiac function and reduces pathologic remodeling in preclinical models of heart failure","volume":"14","author":"Yurista","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026092022202928000_xvag193-B10","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.123.067971","article-title":"Cardiovascular effects of oral ketone ester treatment in patients with heart failure with reduced ejection fraction: a randomized, controlled, double-blind trial","volume":"149","author":"Berg-Hansen","year":"2024","journal-title":"Circulation"},{"key":"2026092022202928000_xvag193-B11","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.124.069732","article-title":"Randomized crossover trial of 2-week ketone ester treatment in patients with type 2 diabetes and heart failure with preserved ejection fraction","volume":"150","author":"Gopalasingam","year":"2024","journal-title":"Circulation"},{"key":"2026092022202928000_xvag193-B12","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/eurheartj\/ehad087","article-title":"Circulating ketone bodies and cardiovascular outcomes: the MESA study","volume":"44","author":"Shemesh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026092022202928000_xvag193-B13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029960","article-title":"Elevated plasma levels of ketone bodies are associated with all-cause mortality and incidence of heart failure in older adults: the CHS","volume":"12","author":"Niezen","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026092022202928000_xvag193-B14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ehf2.14476","article-title":"Circulating 3-hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fraction","volume":"11","author":"Christensen","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026092022202928000_xvag193-B15","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.tem.2021.07.006","article-title":"Ketone bodies for the failing heart: fuels that can fix the engine?","volume":"32","author":"Yurista","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"2026092022202928000_xvag193-B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061541","article-title":"Fasting plasma ketone bodies are associated with NT-proBNP: a potential mechanism to provide fuel for the failing heart","volume":"13","author":"Palm","year":"2024","journal-title":"J Clin Med"},{"key":"2026092022202928000_xvag193-B17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/ejhf.531","article-title":"A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF","volume":"18","author":"Voors","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026092022202928000_xvag193-B18","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13468","article-title":"Association of beta-hydroxybutyrate with development of heart failure: sex differences in a Dutch population cohort","volume":"51","author":"Flores-Guerrero","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2026092022202928000_xvag193-B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020321","article-title":"Ketone bodies are mildly elevated in subjects with type 2 diabetes mellitus and are inversely associated with insulin resistance as measured by the lipoprotein insulin resistance index","volume":"9","author":"Garcia","year":"2020","journal-title":"J Clin Med"},{"key":"2026092022202928000_xvag193-B20","doi-asserted-by":"publisher","first-page":"xvag189","DOI":"10.1093\/eschf\/xvag189","article-title":"A new protein panel for the diagnosis of HFpEF: combining machine-learning and liquid-chromatography mass-spectrometry proteomics","author":"Hoegl","year":"2026","journal-title":"ESC Heart Fail"},{"key":"2026092022202928000_xvag193-B21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"2026092022202928000_xvag193-B22","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/cvr\/cvab235","article-title":"Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF","volume":"118","author":"Markousis-Mavrogenis","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026092022202928000_xvag193-B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/jors.160","article-title":"mma: an R package for mediation analysis with multiple mediators","volume":"5","author":"Yu","year":"2017","journal-title":"J Open Res Softw"},{"key":"2026092022202928000_xvag193-B24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1042\/cs0890431","article-title":"Interleukin 6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2CI2 myotubes","volume":"89","author":"Ebisui","year":"1995","journal-title":"Clinical Science (Lond)"},{"key":"2026092022202928000_xvag193-B25","doi-asserted-by":"publisher","DOI":"10.23977\/medbm.2024.020119","article-title":"Research progress on IL-6\/STAT 3 signaling pathway in heart failure","volume":"2","author":"Li","year":"2024","journal-title":"MEDS Basic Med"},{"key":"2026092022202928000_xvag193-B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11010-013-1896-z","article-title":"Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1\/3 in HepG2 hepatocyte cells","volume":"388","author":"Chew","year":"2014","journal-title":"Mol Cell Biochem"},{"key":"2026092022202928000_xvag193-B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation 1","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"key":"2026092022202928000_xvag193-B28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.bbalip.2019.04.006","article-title":"Lung cancer-derived extracellular vesicles induced myotube atrophy and adipocyte lipolysis via the extracellular IL-6-mediated STAT3 pathway","volume":"1864","author":"Hu","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2026092022202928000_xvag193-B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.841758","article-title":"Cytokine-mediated STAT3 transcription supports ATGL\/CGI-58-dependent adipocyte lipolysis in cancer cachexia","volume":"12","author":"Gandhi","year":"2022","journal-title":"Front Oncol"},{"key":"2026092022202928000_xvag193-B30","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1210\/me.2002-0190","article-title":"Cross-talk between peroxisome proliferator-activated receptor (PPAR) \u03b1 and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARS suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling","volume":"17","author":"Yoshikawa","year":"2003","journal-title":"Mol Endocrinol"},{"key":"2026092022202928000_xvag193-B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.736245","article-title":"A new biomarker tool for risk stratification in \u201cde novo\u201d acute heart failure (OROME)","volume":"12","author":"Agra-Bermejo","year":"2022","journal-title":"Front Physiol"},{"key":"2026092022202928000_xvag193-B32","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.2337\/db15-1193","article-title":"The acute-phase protein orosomucoid regulates food intake and energy homeostasis via leptin receptor signaling pathway","volume":"65","author":"Sun","year":"2016","journal-title":"Diabetes"},{"key":"2026092022202928000_xvag193-B33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12944-018-0657-0","article-title":"Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning","volume":"17","author":"Han","year":"2018","journal-title":"Lipids Health Dis"},{"key":"2026092022202928000_xvag193-B34","first-page":"299","article-title":"Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon","volume":"22","author":"Beylot","year":"1996","journal-title":"Diabetes Metab"},{"key":"2026092022202928000_xvag193-B35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/IJGM.S102819","article-title":"Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements","volume":"9","author":"Levitt","year":"2016","journal-title":"Int J Gen Med"},{"key":"2026092022202928000_xvag193-B36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2015.10.084","article-title":"High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure","volume":"203","author":"Hammer","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026092022202928000_xvag193-B37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1677\/joe.0.1750467","article-title":"The endotoxin-induced increase of cytokines is followed by an increase of cortisol relative to dehydroepiandrosterone (DHEA) in healthy male subjects","volume":"175","author":"Straub","year":"2002","journal-title":"J Endocrinol"},{"key":"2026092022202928000_xvag193-B38","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/01.CIR.101.14.1634","article-title":"Catecholamines, cardiac-adrenergic receptors, and heart failure","volume":"101","author":"Lefkowitz","year":"2000","journal-title":"Circulation"},{"key":"2026092022202928000_xvag193-B39","doi-asserted-by":"publisher","first-page":"774","DOI":"10.2337\/diab.34.8.774","article-title":"Effect of norepinephrine on ketogenesis, fatty acid oxidation, and esterification in isolated rat hepatocytes","volume":"34","author":"Oberhaensli","year":"1985","journal-title":"Diabetes"},{"key":"2026092022202928000_xvag193-B40","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jacc.2019.12.059","article-title":"Testani JM. Diuretic therapy for patients with heart failure: JACC state-of-the-art review","volume":"75","author":"Felker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026092022202928000_xvag193-B41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects","volume":"167","author":"JRB","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026092022202928000_xvag193-B42","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ejhf.3633","article-title":"Myocardial ketone body oxidation contributes to empagliflozin-induced improvements in cardiac contractility in murine heart failure","volume":"27","author":"SN","year":"2025","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag193\/71237948\/xvag193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag193\/71237948\/xvag193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:20:32Z","timestamp":1789957232000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag193\/8818244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag193","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,27]]},"article-number":"xvag193"}}